Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Promega Corporation has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 6 examiners and 6 art units, showing that nearly every current matter has its own examiner and technical assignment. This pattern supports centralized review of claim strategy, but individual responses should remain tied to each art-unit record.
BOWERS, ERIN M is the busiest examiner, with 2 pending matters. That examiner has the largest identified assignment, while the remaining matters are distributed across other examiners. Counsel should look for portfolio-wide consistency without presuming identical examination concerns.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 3 (50%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWERS, ERIN M | 2 | 54.7% | +9.8% |
| CHI, AMANDA LYNN | 1 | — | — |
| PAK, YONG D | 1 | 74.7% | +14.2% |
| BRADY, KRISTEN WEEKS | 1 | 50.0% | +0.0% |
| MISHRA, DEEPA | 1 | 28.9% | +35.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18655005 | COMPLEMENTATION-BASED TAGS AND REPORTERS FOR DUAL-MODALITY LABELING | BOWERS, ERIN M | — |
| 18595339 | ENGINEERED DNA POLYMERASE WITH REDUCED ARTIFACT FORMATION | PAK, YONG D | — |
| 18457679 | RECOGNITION OF CELLULAR TARGET BINDING BY A BIOACTIVE AGENT USING INTRACELLULAR BIOLUMINESCENCE RESONANCE ENERGY TRANSFER | MISHRA, DEEPA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18595339 | ENGINEERED DNA POLYMERASE WITH REDUCED ARTIFACT FORMATION | PAK, YONG D | — |
| 18457679 | RECOGNITION OF CELLULAR TARGET BINDING BY A BIOACTIVE AGENT USING INTRACELLULAR BIOLUMINESCENCE RESONANCE ENERGY TRANSFER | MISHRA, DEEPA | — |
| Art Unit | Apps |
|---|---|
| 1653 | 2 |
| 4100 | 1 |
| 1683 | 1 |
| 1692 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18655005 | COMPLEMENTATION-BASED TAGS AND REPORTERS FOR DUAL-MODALITY LABELING | BOWERS, ERIN M | 1653 | §103§112 | Non-Final OA | — | Pending | May 03, 2024 |
| 18634518 | POLOXAMER-STABILIZED REAGENTS | CHI, AMANDA LYNN | 4100 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18595339 | ENGINEERED DNA POLYMERASE WITH REDUCED ARTIFACT FORMATION | PAK, YONG D | 1683 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 04, 2024 |
| 18486892 | COELENTERAZINE ANALOGUES | BRADY, KRISTEN WEEKS | 1692 | §103 | Final Rejection | — | Pending | Oct 13, 2023 |
| 18457679 | RECOGNITION OF CELLULAR TARGET BINDING BY A BIOACTIVE AGENT USING INTRACELLULAR BIOLUMINESCENCE RESONANCE ENERGY TRANSFER | MISHRA, DEEPA | 1657 | §103§112 | Non-Final OA | — | Pending | Aug 29, 2023 |
| 18312117 | SPLIT MODIFIED DEHALOGENASE VARIANTS | BOWERS, ERIN M | 1653 | §103 | Non-Final OA | — | Pending | May 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPromega Corporation has 6 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Erin M Bowers has the most, with 2 of Promega Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
